Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin in Combination with Metformin Compared to Sitagliptin in Combination with Metformin in Adult Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Exclusion Criteria

• - Clinically diagnosed with Type I diabetes, known diagnosis of Maturity Onset Diabetes of Young (MODY), secondary diabetes mellitus or diabetes insipidus
• - History of diabetic ketoacidosis
• - Any of the following cardiovascular (CV)/Vascular Diseases within 3 months of the enrollment visit
• * Myocardial infarction
• * Cardiac surgery or revascularization (coronary artery bypass surgery Coronary Artery Bypass Graft [(CABG)]/percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty [(PTCA)])
• * Unstable angina
• * Unstable congestive heart failure (CHF)
• * Transient ischemic attack (TIA) or significant cerebrovascular disease
• * Unstable or previously undiagnosed arrhythmia
• * Congestive heart failure, defined as New York Heart Association (NYHA) Class III and IV, unstable or acute congestive heart failure and/or known left ventricular ejection fraction of ≤ 40%
• - Renal Disease
• - Hepatic Diseases
• - Hematological and Oncological Disease/Conditions
• - Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women
• - Abnormal Free T4